Observational study / 2018
Elevated cerebrospinal fluid TMAO levels were linked to mild cognitive impairment, Alzheimer's disease dementia, and biomarkers of Alzheimer's pathology.
Researchers examined TMAO levels in the cerebrospinal fluid (CSF) of 410 individuals, including 40 with Alzheimer's clinical syndrome, 35 with mild cognitive impairment (MCI), and 335 cognitively-unimpaired participants. After controlling for age, sex, and APOE ε4 genotype, CSF TMAO was higher in individuals with MCI and AD dementia compared to cognitively-unimpaired individuals. In addition, elevated CSF TMAO was associated with biomarkers of AD pathology (phosphorylated tau and phosphorylated tau/Aβ42) and neuronal degeneration (total tau and neurofilament light chain protein).
Shows an association, not proof of cause and effect.
- Study type
- Cross-sectional observational study
- Who was studied
- 410 individuals (40 with Alzheimer's clinical syndrome, 35 with MCI, and 335 cognitively-unimpaired)
- What was measured
- Cerebrospinal fluid (CSF) TMAO levels and relationships with CSF biomarkers of AD and neuronal degeneration
THE PAPER
The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease.
Vogt NM, Romano KA, Darst BF, Engelman CD, Johnson SC, Carlsson CM, Asthana S, Blennow K, Zetterberg H, Bendlin BB, Rey FE. Alzheimers Res Ther, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.